Abstract

Targeted therapies that deliver the expected anti-tumor effects while mitigating the adverse effects are taking the cancer world by storm. The need for such therapies in non-small cell lung cancer (NSCLC), where systemic cytotoxic chemotherapies still remain the backbone of management, is felt more than ever before. Runway success of immunotherapies such as Ipilimumab for melanoma has brought excitement among oncologists. Immune-based treatments are in various stages of evaluation for NSCLC as well. Immunotherapies using strategies of antigen based or cell based vaccines, and blocking immune checkpoints are of substantial interest. Meaningful clinical responses are yet to be reaped from these new treatment modalities.

Original languageEnglish (US)
Pages (from-to)39-47
Number of pages9
JournalWorld Journal of Clinical Oncology
Volume5
Issue number2
DOIs
StatePublished - May 10 2014

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Targeted immunotherapy for non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this